A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Jun 2018
At a glance
- Drugs Tesamorelin (Primary)
- Indications Lipohypertrophy
- Focus Adverse reactions
- Sponsors Theratechnologies
- 01 Jun 2018 Planned End Date changed from 1 Mar 2030 to 1 Jul 2018.
- 01 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 02 May 2016 Planned End Date changed from 1 Jan 2025 to 1 Mar 2030.